Depression often goes unrecognized in primary care among symptomatic diabetes patients, especially in some minorities.
It is unknown to what extent the gap between need and care for depression among patients with diabetes differs across racial/ethnic groups. We compared, by race/ethnicity, the likelihood of clinical recognition of depression (diagnosis or treatment) of patients who reported depressive symptoms in a well-characterized community-based population with diabetes.
We used a survey follow-up study of 20,188 patients with diabetes from Kaiser Permanente Northern California. Analyses were limited to 910 patients who scored 10 or higher on the Patient Health Questionnaire (PHQ-8) which was included in the survey and who had no clinical recognition of depression in the 12 months prior to survey. Clinical recognition of depression was defined by a depression diagnosis, referral to mental health services, or antidepressant medication prescription.
Among the 910 patients reporting moderate to severe depressive symptoms on the survey and who had no clinical recognition in the prior year, 12%, 8%, 8%, 14%, and 15% of African American, Asian, Filipino, Latino, and white patients, respectively, were clinically recognized for depression in the subsequent 12 months. After adjusting for sociodemographics, limited English proficiency, and depressive symptom severity, racial/ethnic minorities were less likely to be clinically recognized for depression compared with whites (relative risk: Filipino: 0.30, African American: 0.62).
More work is needed to understand the modifiable patient and provider factors that influence clinical recognition of depression among diabetes patients from different racial/ethnic groups, and the potential impact of low rates of clinical recognition on quality of care.
Am J Manag Care. 2013;19(5):344-352 A total of 88% of patients with no clinical recognition of depression in the prior year and reporting moderate to severe depressive symptoms on a research survey were not clinically recognized within the subsequent 12 months; Filipinos and African Americans were less likely to be clinically recognized with depression than whites. Depression is one of the most common and costly mental disorders among primary care patients in the United States.1-7 Depression is even more common among people with diabetes, 8-14 among whom it is associated with less adequate self-care (eg, poorer diet, physical inactivity, medication nonadherence, and poorer glycemic control) and poorer quality of life.15-20 Comorbid depression and diabetes has also been linked to increased risk of mortality and cognitive decline.21 Findings from the TRIAD study involving 8790 adults with diabetes enrolled in 10 managed care health plans in 7 states indicate that depressed patients achieve poorer diabetes control compared with patients who were not depressed.17,18 Depression is treated less aggressively in patients with multiple comorbidities22 and among patients with diabetes, depression is often undertreated, particularly in racial/ethnic minority groups.23
Compared with whites, US racial/ethnic minority groups have a greater prevalence of diabetes,24,25 have greater concerns about medication use,26 are more likely to have poorly controlled diabetes,18,27 and experience greater incidence of some of the major complications related to diabetes.26,28 These groups may also receive less adequate treatment for comorbid depression. Depression is underdiagnosed in general29-31 and may be even more so in some racial/ethnic minority groups.1,32,33 While findings from psychiatric epidemiologic studies indicate that rates of depression diagnosis for racial/ethnic minorities are generally lower than those for whites, members of racial/ethnic minority groups diagnosed with clinical depression report a greater burden of depressive symptoms and rate their depression as more severe and disabling than for whites.7,34 Higher rates of depressive symptoms among racial/ethnic minorities despite lower rates of diagnoses may indicate disparities in the rate of clinical recognition of depression.35,36
Randomized controlled trials investigating the efficacy of different depression treatment modalities suggest that reductions in the recurrence of depression may lead to improvements in diabetes-related outcomes such as hemoglobin A1C,26,37 and a recent trial of patient-centered management of depression and chronic disease showed significantly improved control of medical disease and depression, suggesting the utility of depression treatment when tailoring care.38
Despite the well-documented clinical importance of depression for patients with diabetes and epidemiologic evidence of racial/ethnic disparities in diabetes prevalence, diabetes control, and outcomes, there is relatively little research regarding racial/ethnic disparities in the recognition and care of depression among multi-ethnic populations with diabetes in usual care settings. We evaluated whether there were significant racial/ethnic differences in the likelihood that patients with diabetes who self-reported significant depressive symptoms would be diagnosed or treated for depression during a 12 month follow-up. The current study is based on a sample drawn from a single integrated healthcare delivery system, which may reduce confounding by access to care.
Study participants were drawn from the Diabetes Study of Northern California (DISTANCE), a follow-up study among members of the Kaiser Permanente Northern California Diabetes Registry conducted in 2005-2006. Kaiser Permanente, an integrated, non-profit, group-practice healthcare delivery organization, provides comprehensive medical services to over 3 million members in Northern California, more than 25% of the region’s population. Care is provided by more than 7000 providers at 19 hospitals and 152 medical offices. Kaiser Permanente members are predominantly employed or retired individuals and closely approximate the general population of the region ethnically and socioeconomically except for the extreme tails of the income distribution.
DISTANCE was designed to assess the association of patient, provider, and health system factors with health outcomes among patients with diabetes from 5 racial/ethnic groups. A randomly selected, ethnically stratified sample of members with diabetes receiving care from Kaiser Permanente Northern California (“Kaiser Permanente”) was invited in 2005 to 2006 to complete the survey. Of these, 20,188 patients (62% response rate among eligible members) completed surveys: 3420 African Americans (16.9%), 2312 Asians (excluding Filipinos) (11.4%), 4602 whites (22.8%), 2404 Filipinos (11.9% [we examined Filipinos separately from the broader Asian racial/ethnic group because Filipinos had a significantly different sociodemographic profile compared with the Asian group. While the DISTANCE sample did include other Pacific Islander groups, the numbers were substantially lower, so they were combined into 1 category which also included Native Americans, Eskimo, multiracial, and other/unknown]), 3717 Latinos (18.4%), 2222 multiracial (11.0%), and 1511 other (7.5%). Demographic, clinical, behavioral, and census data were available for all invited participants. No response bias was detected when comparing, among responders versus non-responders, the associations of poor glycemic control (A1C >9%) with race (P = 0.55); subsequent assessments of selection bias also failed to detect response biases.39
The DISTANCE survey took an average of 45 to 60 minutes to complete and included 4 modes of administration: 1) a computer-assisted telephone interview (CATI) administered by a third party, 2) a password-enabled, Internet-accessible survey (“web survey”) maintained on a secure server at the Kaiser Division of Research, 3) a self-administered, written survey, or 4) a short version of the written survey (the short written version was abridged and contained 40 questions). Offering the survey by oral interview in multiple languages was intended to mitigate the language and/or literacy barriers. The written and web surveys were in English only, but the CATI was available in English, Spanish, Cantonese, Mandarin, and Tagalog, using certified translations of an English script. The content of each survey mode was identical except for slight adjustments in wording as needed. Details on study recruitment procedures and sample characteristics have been published previously.40 The DISTANCE study was approved by the Institutional Review Boards of the Kaiser Foundation Research Institute and the University of California, San Francisco.
Self-Reported Depressive Symptoms
The survey included the 8-item Patient Health Questionnaire (PHQ-8), a validated screener for depression, which has been found to function similarly across different racial and ethnic groups.41 The PHQ-8 yields a valid proxy of depression diagnosis compared with other, longer clinician-administered diagnostic instruments and is widely used in clinical practices, including Kaiser Permanente.42 The PHQ-8 was used to identify current depressive symptoms. The self-report questionnaire consists of 8 out of the 9 Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, depressive disorder criteria: anhedonia, depressed mood, trouble sleeping, loss of energy, changes in appetite, trouble concentrating, and psychomotor retardation or agitation experienced over the last 2 weeks. In line with current practice, patients who scored >10 were classified as meeting criteria for depression care.41 We also examined severity of depressive symptoms using validated cut points for depression severity: moderate (PHQ score 10-14), moderatesevere (PHQ score 15-19), and severe (PHQ score >19).41
Clinically Recognized Depression
Clinically recognized depression (CRD) was our outcome of interest. Similar to previous studies, CRD was determined by the presence of a diagnosis, referral, or treatment of depression in the patient’s medical records.42,43 More explicitly, CRD was defined by the presence of any of the following within 12 months following respondents’ participation in the DISTANCE survey: 1) the diagnosis of depression in patient’s history/medical chart (International Classification of Diseases, Ninth Edition codes 296.2X, 296.3X, 296.5X, 296.8X, 296.9X, 300.4X, 309.0X, 309.1X, 309.2X, 311, 648.4X, V790, or 307.44), 2) physician referral to mental health services for depression treatment captured electronically within the Kaiser Permanente system, and/or 3) prescription written for first-line anti-depressant medications (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, or escitalopram). We included diagnoses and treatments regardless of the clinical setting from which they were generated (eg, primary care visits or mental health visits).
There were 10,543 DISTANCE respondents who selfidentified as African American/black, Asian, Filipino, Latino, or white (). Of these, 1370 (13%) met criteria for moderate to severe depression according to the PHQ-8 (score >10)41 on the DISTANCE survey. We excluded the 33.1% (460/1370) of these who had been clinically recognized by a Kaiser Permanente provider in the 12 months prior to DISTANCE survey participation and limited our analyses to the remaining 910 patients with self-reported depressive symptoms and no diagnosis, referral, or treatment for depression in the prior year. Within our study cohort, 24% (217/910) had an earlier history (ie, more than 12 months prior to the survey) of CRD within Kaiser medical records.
Covariates included sociodemographic factors, including respondents’ age and gender, depression symptom severity, limited English proficiency, number of medical visits, and patients’ level of medical illness severity using the Deyo version of the Charlson Comorbidity Index.44,45 Age at survey completion was included as a continuous variable. Limited English proficiency was a binary variable defined as respondents’ selfreported difficulty in reading or speaking English.
All data were analyzed using SAS version 9.13.46 We evaluated whether there were racial/ethnic differences in the likelihood of CRD during 12 months of follow-up after the survey among patients who self-reported significant depressive symptoms in the DISTANCE survey. We used modified Poisson regression models to obtain relative risk estimates to examine the association between race/ethnicity and likelihood of CRD.47,48 Results from previous studies suggest that modified Poisson regression is a superior method to log binomial regression for estimating relative risks when examining prospective data with binary outcomes.49 Estimated relative risk (RR) and 95% confidence intervals were generated using a robust error variance procedure known as sandwich estimation,48 which was implemented using the SAS PROC GENMOD procedure with the REPEATED statement.46 We first created unadjusted Poisson regression models to test for racial/ethnic differences in CRD. Given the race-stratified random sampling design, all models were weighted for sampling fractions (expansion weighting). Weighting for sampling fractions compensates for the unequal probability potential respondents in the sample population had in being selected into the DISTANCE study.50-52 Although the clinical recognition of depression should not depend on whether someone is of a particular race/ethnicity, sex, age, or clinical state, we specified additional models adjusted for age, sex, depression symptom severity, number of visits, and limited English proficiency. Finally, we examined whether there was effect modification by sex by specifying interaction terms between race/ethnicity and sex.
There were some significant differences in sociodemographic characteristics of the racial/ethnic groups. African Americans were, on average, older and Latinos were younger compared with the other racial/ethnic groups (see ), while African American, Latino, and Filipino subgroups had relatively higher proportions of women versus men compared with Asians and whites. Education also varied: Latinos were the least likely to have completed high school while Filipinos, Asians, and whites were the most likely to report having a college degree. There were no significant racial/ethnic differences in the distribution of depression symptom severity based on the self-reported screener (PHQ-8). There were significant differences in the number of medical visits across racial/ethnic groups. On average, African Americans had the highest number of visits during the follow-up period and Asians had the fewest number of visits. This utilization pattern tracked the significant differences in comorbidity burden, with the highest levels in African Americans, lowest in Asians, and intermediate and similar in Filipinos, Latinos, and whites.
Our first finding concerns the rate of CRD during the 12 months after self-reporting moderate to severe depressive symptoms (PHQ-8 >10) on our survey, among those whose depression was not currently recognized in the medical system (ie, no CRD in the prior 12 months). In this sample, 12% (110/910) overall (12%, 8%, 8%, 14%, and 15% of African American, Asian, Filipino, Latino, and white patients, respectively), were clinically recognized (ie, diagnosed, referred, or treated for depression) within 12 months of each individual’s survey date. The second finding concerns the relative differential in rates of clinical recognition across racial/ethnic groups (Table 2). In the unadjusted model, patients from each of the 4 racial/ethnic minority groups were less likely than whites to be clinically recognized for depression within 12 months, although the absolute differences in rates were small and were statistically significant only for Filipinos (RR, 0.33; 95% confidence interval [CI], 0.17-0.65). Across all models, Filipinos remained significantly less likely to have CRD compared with whites. While Asians were less likely to have CRD compared with whites, these differences were not significant in any model. For Latinos and African Americans, differences were evident in some models but not others. Latinos were less likely than whites to have CRD when adjusted for age and sex in Model 2 (RR, 0.58; CI, 0.36-0.95) and for age, sex, depression severity, and limitations on English proficiency in Model 3 (RR, 0.53; CI, 0.29 to 0.97), but this was not significant either in the initial unadjusted model or when further adjusted for medical visits in Model 4 (RR, 0.57; CI, 0.31-1.04) and Charlson index in Model 5 (RR, 0.57; CI, 0.31-1.05). Differences in CRD between African Americans and whites were not significant in Models 1 to 3, but became significant once analyses were further adjusted for medical visits in Model 4 (RR, 0.58; CI, 0.35-0.97) and remained significant in Model 5 after adjusting for the Charlson index (RR, 0.58; CI, 0.35-0.97).
Finally, we tested whether the race/ethnic differences in CRD were modified by sex but we found no statistically significant interactions between race/ethnicity and gender in ourmodels of CRD, indicating that the patterns of clinical recognition variation across racial/ethnic groups were similar for men and women (analysis not shown).
The first finding from this study was that among patients with diabetes who had significant depressive symptoms and who had not been clinically recognized with depression in the prior year, few (less than 15%) were clinically recognized any time during the following year. This finding is consistent with the prior evidence regarding the underrecognition of depression in populations with diabetes from primary care settings.53 In the current study design, we excluded the 34% (460/1370) of subjects with PHQ-8 scores consistent with depression who had been clinically recognized in the previous 12 months; this exclusion may have resulted in a study sample with a lower likelihood of subsequent depression recognition. Rates of recognition may also have increased in recent years within the Kaiser system with the subsequent introduction of regular screening and prioritization of care for depressive symptoms in routine diabetes care within the Kaiser system.
Low rates of clinically recognized depression may be due to provider or patient factors; both may be uncomfortable about discussing symptoms of depression and patients may want to avoid the stigma sometimes associated with a diagnosis of depression. There may also be cultural differences in communication style and in what is seen as appropriate to share in a medical encounter.
The second finding involved differences in clinical recognition of patients from different racial/ethnic groups. While the absolute differences in the rate of clinical recognition of depression was not marked across race/ethnic groups, there were noteworthy relative differences. In models adjusted for age, sex, limited English proficiency, depression symptom severity, and number of medical visits, Filipinos and African Americans both had significantly lower CRD than did whites. The finding that Filipinos but not Asians had significantly lower CRD points to the importance of analyzing these groups separately when studying health disparities.54
Outpatient visit frequency differed by race/ethnicity, with African Americans having more visits. The greater number of outpatient visits among African Americans should provide more opportunities for clinical recognition of depression and we expected that controlling for the number of visits would, if anything, reduce the difference in CRD for African Americans versus whites. However, adjusting for the number of medical visits had minimal impact on point estimates, and the difference in the risk of being clinically recognized became significantly different compared with whites. Further adjustment for comorbidity burden did not alter the point estimates in a substantive way and thus did not confound or explain the observed patterns.
The respondents in this study were drawn from an integrated, not-for-profit healthcare delivery system that includes mental healthcare treatment services and uses established treatment protocols, both of which should reduce inequities in recognition of depression. Despite this, some differences in CRD were found which were statistically significant although relatively small in absolute terms. It is unclear to what extent the racial/ethnic differences observed here reflect differences in a patient’s willingness to communicate depressive symptoms to their healthcare provider, differences in likelihood of offered treatment, or differences in a clinician’s elicitation or assessment of patient reports of depressive symptoms across racial/ ethnic groups. A special strength of this study is that the 2 indicators of CRD based on offered care (ie, referral to a mental health specialist and a prescription for an antidepressant) are based on the electronic referral and prescribing systems and do not depend on utilization (ie, the patient actually attending that mental health visit or picking up that prescription).
Several potential limitations could affect the results of this study. While there are advantages of having data from a single integrated healthcare delivery system, this limits the generalizability of findings to patients with diabetes receiving care in other types of healthcare settings (eg, safety net or for-profit settings) and in other areas of the United States. It is also likely that the rates of clinical recognition, and possibly race/ethnic differences, which we observed here would be worse for patients in more fragmented health systems or population-based studies.
Aspects of the study design could have contributed to an underestimation of the actual rate of clinical recognition of depression. Although a PHQ-8 score of >10 has high sensitivity and specificity (88%) for major depression compared with interviews by mental health professionals,17,41 the PHQ-8 does not ensure that respondents would be considered clinically depressed by a provider. Additionally, because we excluded patients who had already been clinically recognized with depression during the 12 months prior to the survey, participants could be at higher risk for unrecognized depression, including being reticent to discuss mental health symptoms with providers. Patients were surveyed confidentially about their depressive symptoms and, in accordance with our agreement with those responding to the survey, the results were not shared with their providers. Finally, there is no way to gauge how long the self-reported depressive symptoms may have lasted after participation in the survey. Katon et al found that 62% of patients with diabetes who reported symptoms consistent with major depression had been experiencing a chronic form of depression (dysthymia) in the previous 2 or more years.43 Additionally, we are unable to ascertain whether patients received a diagnosis and/or treatment outside this health delivery system. While this potentially limits the overall inferences that could be drawn from these data regarding the rate of clinical recognition, we have no reason to expect this would differ substantively across race/ethnicity.
Accounting for Differences in Diagnoses and Treatment
The mental health services literature provides several potential explanations for racial/ethnic disparities in clinical recognition of depression. One issue could be that responses on the PHQ-8 are less prognostic of depression for racial/ethnic groups other than whites, resulting in more false positives among racial/ethnic minorities. However, evidence from previous studies does not indicate significant racial/ethnic differences in the factor structure of the PHQ-8 or in correlations with level of depression symptom severity.34,55 A second issue raised in population-based studies is whether access to and quality of mental healthcare services account for racial/ethnic disparities in rates of depression recognition.56,57 However, all participants in the current sample were drawn from the same integrated healthcare delivery system, so some quality of care and care access issues such as insurance coverage should be reduced. Finally, although language barriers could lead to poorer depression recognition in some racial/ethnic groups,58 we found no differences in effect estimates when we adjusted for patient-limited English proficiency.
Future research should work toward developing patient-centered and culturally sensitive approaches to recognition of depression in primary care. The observed race/ethnic differences in clinical recognition of depression may be attributable to patient factors, provider factors, or both. For instance, racial/ethnic differences in likelihood of clinical recognition could be attributable to cultural norms regarding expression of distress and communication with providers (Kohn-Wood LP, Banks KH, Hudson G, Ivey A, unpublished data).35,36,59 Several studies have suggested that differences in the manifestation of depressive symptoms, including reporting somatic symptoms, may be related to underdiagnosis of depression, particularly among Latinos and Asian Americans.32,34,60,61Depressive symptoms have been misinterpreted as diabetes distress in previous studies.62-64 Greater research efforts pursuing deeper investigations of culture-bound presentations within different racial/ethnic groups are necessary to address both issues.
Future research should also explore how physicianpatient communication affects a provider’s ability to recognize depression. Depression may impede effective communication, making it more difficult for clinicians to elicit and assess depressive symptoms.65 There may also be cultural differences in a patient’s terminology in expressing depressive symptoms, in beliefs about the causes and expression of depression, in norms about the communication of depressive feelings outside of the privacy of the home, and in patients’ treatment preferences and acceptability of depression treatment.66-68 Overcoming these barriers will require education of providers about cultural experiences and expression of depressive symptoms and of patients to reduce stigma around mental health and encourage patient awareness of depression and willingness to seek help when they experience depressive symptoms.
Additionally, researchers should continue to examine how factors such as perceptions of racial discrimination within the healthcare system and mistrust of providers could affect patients’ willingness to share experiences of depressive symptoms with physicians. Provider bias has been shown to affect whether individuals from different racial/ethnic groups are diagnosed with depression and what type of care is offered.33,35,69,70 For instance, some researchers have argued that the greater rates of schizophrenia diagnosis and lower rates of depression diagnosis among African Americans could be attributed to differences in the perspectives of clinicians versus patients as well as in clinical presentation.33,35,71,72
Our study is consistent with a previous publication by Katon et al53 which also reported large gaps in recognition of depression among patients with comorbid depression and diabetes in a similar healthcare delivery system. The current study also suggests that these gaps in clinical recognition are particularly apparent for certain minority groups. All patients in this sample self-reported depressive symptoms, as indicated by scores on the PHQ-8, and had not been clinically recognized in the previous 12 months. Their depressive symptoms would reasonably warrant subsequent attention from providers. These patients with diabetes were likely to be seeing their physicians more often than patients without chronic diseases, and would have more opportunities to be clinically recognized. Even if the exclusion of participants who had been clinically recognized in the previous 12 months may have increased the chances that those in the sample were a select sample more prone to not being clinically recognized, our findings that approximately 88% of the patients showed no evidence of clinical recognition within the year following the survey indicates a need to explore ways to increase rates of clinical recognition. Further, our finding that clinical recognition differs by race/ ethnicity suggests that cultural differences or communication style may be important.
The failures to diagnose or treat depression among patients with diabetes may add to their already substantial health burden, impact negatively their quality of life, and potentially contribute to future diabetes-related complications. Moreover, differences in depression recognition across race/ethnic groups may be modifiable and deserve further investigation. Our ability to effectively and uniformly recognize depression in a timely fashion among patients with diabetes is particularly important given the evidence of effective interventions to treat both depression and diabetes.37Acknowledgments The authors wish to thank David Chae for his contribution.
Author Affiliations: From George Warren Brown School of Social Work (DLH), Washington University in St. Louis, St. Louis, MO; Kaiser Permanente Division of Research (AJK, MP, ASA, HHM, JZ), Oakland, CA; Division of General Internal Medicine (AF, DS), University of California, San Francisco, CA: Center for Health and Community (NEA), University of California, San Francisco, CA.
Funding Source: This work was supported by the National Institute of Diabetes, Digestive and Kidney Diseases Grant Numbers: R01 DK081796, RC1 DK086178, R01 DK65664, and P30 DK092924, and the National Institute of Child Health and Human Development: Grant Number: R01 HD046113 with additional support from the Kellogg Health Scholars Program, the Robert Wood Johnson Health and Society Fellows Program, the University of California, San Francisco Center on Research in Social Disparities and Center for Health & Community.
Author Disclosures: Dr Schillinger reports that he has received consulting fees from Kaiser for his participation in NIH-funded research. The other authors (DLH, AJK, AF, MP, ASA, HHM, NEA) report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.
Authorship Information: Concept and design (DLH, AJK, ASA, DS, NEA); acquisition of data (AJK, MP, DS, HHM, JF, NEA); analysis and interpretation of data (DLH, AJK, AF, MP, ASA, DS, JF, NEA); drafting of the manuscript (DLH, AJK, AF, DS, NEA); critical revision of the manuscript for important intellectual content (DLH, AJK, AF, MP, ASA, DS, HHM, NEA); statistical analysis (AJK, MP, JF); provision of study materials or patients (AJK, HHM); obtaining funding (AJK, DS, HHM); administrative, technical, or logistic support (HHM); and supervision (AJK, DS, NEA).
Address correspondence to: Andrew J. Karter, PhD, Senior Investigator, Associate Director, Center for Diabetes Translational Research, Kaiser Permanente-Division of Research, 2000 Broadway, Oakland, CA 94612. E-mail: firstname.lastname@example.org. 1. Borowsky S, Rubenstein L, Meredith L, Camp P, Jackson-Triche M, Wells K. Who is at risk of nondetection of mental health problems in primary care? J Gen Intern Med. 2000;15(6):381-388.
2. Mullan E, Katona P, D’ath P, Katona C. Screening, detection and management of depression in elderly primary care attenders: II: detection and fitness for treatment: a case record study. Fam Pract.1994;11(3):267-270.
3. The WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004;291(21):2581-2590.
4. Üstün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJL. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;184:386-392.
5. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617-627.
6. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64(12):1465-1475.
7. Williams DR, Gonzalez HM, Neighbors H, et al. Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the National Survey of American Life. Arch Gen Psychiatry. 2007;64(3):305-315.
8. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes. Diabetes Care. 2001;24(6):1069-1078.
9. de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001;63(4):619-630.
10. Lloyd CE. Diabetes and mental health; the problem of co-morbidity. Diabet Med. 27(8):853-854.
11. Holt RIG, Phillips DIW, Jameson KA, et al. The relationship between depression and diabetes mellitus: findings from the Hertfordshire Cohort Study. Diabet Med. 2009;26(6):641-648.
12. Evette JL, Wayne K, Joan R, et al. Depression and diabetes symptom burden. Gen Hosp Psychiatry. 2004;26(6):430-436.
13. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan. Diabetes Care. 2008;31(12):2383-2390.
14. Rustad JK, Musselman DL, Nemeroff CB. The relationship of depression and diabetes: pathophysiological and treatment implications. Psychoneuroendocrinology. 2011;36(9):1276-1286.
15. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med. 2000;160(21):3278-3285.
16. Lloyd CE, Pambianco G, Orchard TJ. Does diabetes-related distress explain the presence of depressive symptoms and/or poor self-care in individuals with Type 1 diabetes? Diabet Med. 27(2):234-237.
17. Waitzfelder B, Gerzoff RB, Karter AJ, et al. Correlates of depression among people with diabetes: the Translating Research Into Action for Diabetes (TRIAD) study. Prim Care Diabetes. 2010;4(4)215-222.
19. Gonzalez JS, Safren SA, Cagliero E, et al. Depression, self-care, and medication adherence in type 2 diabetes. Diabetes Care. 2007;30(9): 2222-2227.
20. Laiteerapong N, Karter AJ, Liu JY, et al. Correlates of quality-of-life in older adults with diabetes [published online June 2, 2011]. Diabetes Care. 2011;34(8):1749-1753.
21. Katon W, Lin E, Williams L, et al. Comorbid depression is associated with an increased risk of dementia diagnosis in patients with diabetes: a prospective cohort study. J Gen Internal Medicine. 2010;25(5):423-429.
22. Gill JM, Klinkman MS, Chen YX. Antidepressant medication use for primary care patients with and without medical co-morbidities: a national electronic health record (EHR) network study. J Am Board of Family Medicine. 2010;23(4):499-508.
23. Li C, Ford ES, Zhao G, Ahluwalia IB, Pearson WS, Mokdad AH. Prevalence and correlates of undiagnosed depression among U.S. adults with diabetes: the Behavioral Risk Factor Surveillance System, 2006. Diabetes Res and Clin Pract. 2009;83(2):268-279.
24. Flegal KM, Ezzati TM, Harris MI, et al. Prevalence of diabetes in Mexican Americans, Cubans, and Puerto Ricans from the Hispanic Health and Nutrition Examination Survey, 1982-1984. Diabetes Care. 1991;14(7):628-638.
25. Harris MI. Epidemiological correlates of NIDDM in Hispanics, whites, and blacks in the U.S. population. Diabetes Care. 1991;14(7):639-648.
26. Huang ES, Brown SES, Thakur N, et al. Racial/ethnic differences in concerns about current and future medications among patients with type 2 diabetes. Diabetes Care. 2009;32(2):311-316.
27. Duru OK, Gerzoff RB, Selby JV, et al. Identifying risk factors for racial disparities in diabetes outcomes: the Translating Research Into Action for Diabetes Study. Med Care. 2009;47(6):700-706. 710.1097/MLR.1090b1013e318192609d.
28. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA. 2002;287(19):2519-2527.
29. Nutting PA, Gallagher K, Riley K, et al. Care management for depression in primary care practice: findings from the RESPECT-Depression Trial. Ann Fam Med. 2008;6(1):30-37.
30. Freeling P, Rao BM, Paykel ES, Sireling LI, Burton RH. Unrecognised depression in general practice. Br Med J (Clin Res Ed). 1985;290(6485):1880-1883.
31. Perez-Stable EJ, Miranda J, Munoz RF, Ying Y-W. Depression in medical outpatients: underrecognition and misdiagnosis. Arch Intern Med. 1990;150(5):1083-1088.
32. Chung H, Teresi J, Guarnaccia P, et al. Depressive symptoms and psychiatric distress in low income Asian and Latino primary care patients: prevalence and recognition. Community Ment Health J. 2003;39(1):33-46.
33. Das AK, Olfson M, McCurtis HL, Weissman MM. Depression in African Americans: breaking barriers to detection and treatment. J Fam Pract. 2006;55(1):30-39.
34. Huang FY, Chung H, Kroenke K, Spitzer RL. Racial and ethnic differences in the relationship between depression severity and functional status. Psychiatr Serv. 2006;57(4):498-503.
35. McGuire TG, Miranda J. New evidence regarding racial and ethnic disparities in mental health: policy implications. Health Aff. 2008;27(2):393-403.
36. Alegria M, McGuire T. Rethinking a universal framework in the psychiatric symptom-disorder relationship. J Health Soc Behav. 2003;44(3):257-274.
37. Lustman PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE. Cognitive behavior therapy for depression in type 2 diabetes mellitus. Ann Intern Med. 1998;129(8):613-621.
38. Katon WJ, Lin EHB, von korff M, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010;363(27):2611-2620.
39. Sarkar U, Karter A, Liu J, Moffet H, Adler N, Schillinger D. Hypoglycemia is more common among type 2 diabetes patients with limited health literacy: the Diabetes Study of Northern California (DISTANCE). J Gen Intern Med. 2010;25(9):962-968.
40. Moffet HH, Adler NE, Schillinger D, et al. Cohort profile: the diabetes study of northern California (DISTANCE)-objectives and design of a survey follow-up study of social health disparities in a managed care population. Int J Epidemiol. 2008;38(1):38-47.
41. Kroenke K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1-3):163-173.
42. Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): adiagnostic meta-analysis. J Gen Intern Med. 2007;22(11):1596-1602.
43. Katon W, Von Korff M, Ciechanowski P, et al. Behavioral and clinical factors associated with depression among individuals with diabetes. Diabetes Care. 2004;27(4):914-920.
44. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
45. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
46. SAS Software [computer program]. Version 9.13. Cary, NC: SAS Institute, Inc; 2010.
47. Zocchetti C, Consonni D, Bertazzi P. Estimation of prevalence rate ratios from cross-sectional data. Int J Epidemiol. 1995;24(5):1064-1065.
48. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702-706.
49. Yelland LN, Salter AB, Ryan P. Performance of the modified poisson regression approach for estimating relative risks from clustered prospective data. Am J Epidemiol. 2011;174(8):984-992.
50. Heeringa SG, Liu J. Complex sample design effects and inference for mental health survey data. John Wiley Sons, Ltd; 2006.
51. Heeringa SG, Wagner J, Torres M, Duan NH, Adams T, Berglund P. Sample designs and sampling methods for the Collaborative Psychiatric Epidemiology Studies (CPES). Int J Methods Psychiatr Res. 2004;13(4):221-240.
52. Groves RM, Fowler FJ, Couper MP, Lepkowski JM, Singer E, Tourangeau R. Survey Methodolgy. Hoboken, NJ: John Wiley & Sons; 2004.
53. Katon WJ, Simon G, Russo J, et al. Quality of depression care in a population-based sample of patients with diabetes and major depression. Med Care. 2004;42(12):1222-1229.
54. Kanaya AM, Adler N, Moffet HH, et al. Heterogeneity of diabetes outcomes among asians and Pacific Islanders in the US: the Diabetes Study of Northern California (DISTANCE). Diabetes Care. 2011;34(4):930-937.
55. Huang F, Chung H, Kroenke K, Delucchi K, Spitzer R. Using the patient health questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. J Gen Intern Med. 2006;21(6):547-552.
56. Gonzalez HM, Vega WA, Williams DR, Tarraf W, West BT, Neighbors HW. Depression care in the United States: too little for too few. Arch Gen Psychiatry. 2010;67(1):37-46.
57. Alegria M, Chatterji P, Wells K, et al. Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatr Serv. 2008;59(11):1264-1272.
58. Diaz E, Miskemen T, Vega WA, et al. Inconsistencies in diagnosis and symptoms among bilingual and English-speaking Latinos and Euro-Americans. Psychiatr Serv. 2009;60(10):1379-1382.
59. Snowden LR. Bias in mental health assessment and intervention: theory and evidence. Am J Public Health. 2003;93(2):239-243.
60. Gwynn RC, McQuistion HL, McVeigh KH, Garg RK, Frieden TR, Thorpe LE. Prevalence, diagnosis, and treatment of depression and generalized anxiety disorder in a diverse urban community. Psychiatr Serv. 2008;59(6):641-647.
61. Lewis-Fernandez R, Das AK, Alfonso C, Weissman MM, Olfson M. Depression in US Hispanics: diagnostic and management considerations in family practice. J Am Board Fam Pract. 2005;18(4):282-296.
62. Fisher L, Skaff MM, Mullan JT, et al. Clinical depression versus distress among patients with type 2 diabetes. Diabetes Care. 2007;30(3):542-548.
63. Fisher L, Glasgow RE, Mullan JT, Skaff MM, Polonsky WH. Development of a brief diabetes distress screening instrument. Ann Fam Med. 2008;6(3):246-252.
64. Fisher L, Mullan JT, Arean P, Glasgow RE, Hessler D, Masharani U. Diabetes distress but not clinical depression or depressive symptoms is associated with glycemic control in both cross-sectional and longitudinal analyses. Diabetes Care. 2010;33(1):23-28.
65. Swenson SL, Rose M, Vittinghoff E, Stewart A, Schillinger D. The influence of depressive symptoms on clinician-patient communication among patients with type 2 diabetes. Med Care. 2008;46(3):257-265 210.1097/MLR.1090b1013e31816080e31816089.
66. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005;293(16):1995-2002.
67. Cooper LA, Gonzales JJ, Gallo JJ, et al. The acceptability of treatment for depression among African-American, Hispanic, and white primary care patients. Med Care. 2003;41(4):479-489.
68. Cooper-Patrick L, Powe NR, Jenckes MW, et al. Identification of patient attitudes and preferences regarding treatment of depression. J Gen Intern Med. 1997;12(7):431-438.
69. Neighbors HW, Jackson JS, Campbell L, Williams D. The influence of racial factors on psychiatric diagnosis: a review and suggestions for research. Community Ment Health J. 1989;25(4):301-311.
70. Trierweiler SJ, Muroff JR, Jackson JS, Neighbors HW, Munday C. Clinician race, situational attributions, and diagnoses of mood versus schizophrenia disorders. Cultur Divers Ethnic Minor Psychol. 2005;11(4):351-364.
71. Whaley A. Cultural mistrust and the clinical diagnosis of paranoid schizophrenia in African American patients. J Psychopathol Behav Assess. 2001;23(2):93-100.
72. Baker FM, Bell CC. Issues in the psychiatric treatment of African Americans. Psychiatr Serv. 1999;50(3):362-368.
18. Selby JV, Swain BE, Gerzoff RB, et al. Understanding the gap between good processes of diabetes care and poor intermediate outcomes: translating research into action for diabetes (TRIAD). Med Care. 2007;45(12):1144-1153. 1110.1097/MLR.1140b1013e3181468e3181479.